Parkinson's Disease Market Size, Share, Global Insights and Analysis

According to Global Markets Direct's, recently published report 'Parkinson's Disease – Pipeline Review, H1 2016'; Parkinson's Disease pipeline therapeutics constitutes close to 345 molecules. Out of which approximately 282 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, Global Markets Direct says; Parkinson's Disease Parkinson's disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson’s disease. Parkinson’s disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

The report 'Parkinson's Disease – Pipeline Review, H1 2016' outlays comprehensive information on the therapeutics under development for Parkinson's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Browse full report with TOC@ https://marketreportscenter.com/reports/338305/parkinsons-disease-pipeline-review-h1-2016

It also reviews of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 23, 35, 4, 162, 41 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical, Discovery and Unknown stages comprises 1, 46, 15 and 1 molecules, respectively....